Cargando…

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat HCC, such as targeted tyrosine kinase inhibitors, immune based therapies and combination of chemotherapy. However, limitation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Danyu, Liu, Chan, Qin, Mengyao, Zhang, Xiao, Xi, Tao, Yuan, Shengtao, Hao, Haiping, Xiong, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897153/ https://www.ncbi.nlm.nih.gov/pubmed/35256934 http://dx.doi.org/10.1016/j.apsb.2021.09.019

Ejemplares similares

GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway
por: Wang, Hongxv, et al.
Publicado: (2022)

Glutamine Metabolism Scoring Predicts Prognosis and Therapeutic Resistance in Hepatocellular Carcinoma
por: Ying, Leqian, et al.
Publicado: (2021)

Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis
por: Lee, Sunjae, et al.
Publicado: (2016)

Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
por: Wu, Yao, et al.
Publicado: (2020)

Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction
por: Dumenci, Ozbil E, et al.
Publicado: (2020)

Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma
por: Shen, J, et al.
Publicado: (2016)

The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications
por: Gungor, Medine Zeynep, et al.
Publicado: (2022)

Dysregulation of Wnt/β‐catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application
por: Li, Qian, et al.
Publicado: (2021)

Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma
por: Li, Keren, et al.
Publicado: (2023)

Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics
por: Flores, Avegail, et al.
Publicado: (2014)

STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma
por: Lee, Carol, et al.
Publicado: (2019)

Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling
por: Liang, Jessie Qiaoyi, et al.
Publicado: (2018)

Dysregulated microRNAs in Hepatitis B Virus-Related Hepatocellular Carcinoma: Potential as Biomarkers and Therapeutic Targets
por: Xu, Jinghang, et al.
Publicado: (2020)

Transcription Factors and Methylation Drive Prognostic miRNA Dysregulation in Hepatocellular Carcinoma
por: Qin, Shijie, et al.
Publicado: (2021)

The emergence of long non-coding RNAs in hepatocellular carcinoma: an update
por: Peng, Li, et al.
Publicado: (2018)

Characterization of metabolic landscape in hepatocellular carcinoma
por: Wu, Jing, et al.
Publicado: (2021)

Hepatocellular carcinoma cell differentiation trajectory predicts immunotherapy, potential therapeutic drugs, and prognosis of patients
por: Qiu, Jun, et al.
Publicado: (2023)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma
por: Yuan, Xiaofeng, et al.
Publicado: (2022)

Dysregulated serum response factor triggers formation of hepatocellular carcinoma
por: Ohrnberger, Stefan, et al.
Publicado: (2015)

Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma
por: Zheng, Hao, et al.
Publicado: (2017)

Alcohol-dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma
por: Zheng, Hao, et al.
Publicado: (2017)

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
por: Qing, Xin, et al.
Publicado: (2021)

Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway
por: Gao, Qingzhu, et al.
Publicado: (2022)

Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities
por: De Matteis, Serena, et al.
Publicado: (2018)

TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
por: Todisco, Simona, et al.
Publicado: (2019)

Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop
por: Lin, Sensen, et al.
Publicado: (2017)

Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
por: Bengochea, A, et al.
Publicado: (2008)

Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance
por: Raghunath, Azhwar, et al.
Publicado: (2018)

Dysregulation of phosphoproteins in hepatocellular carcinoma revealed via quantitative analysis of the phosphoproteome
por: Liu, Yixian, et al.
Publicado: (2021)

Dysregulated paired related homeobox 1 impacts on hepatocellular carcinoma phenotypes
por: Piorońska, Weronika, et al.
Publicado: (2021)

Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma
por: Qi, Feng, et al.
Publicado: (2023)

The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma
por: Qin, Sha, et al.
Publicado: (2022)

Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma
por: Xie, Xuancheng, et al.
Publicado: (2022)

Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review)
por: Luo, Wenyu, et al.
Publicado: (2022)

Elevated Expression of Cytosolic Phospholipase A2Delta Is Associated with Lipid Metabolism Dysregulation during Hepatocellular Carcinoma Progression
por: Ranjpour, Maryam, et al.
Publicado: (2020)

Corrigendum to “Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway”
por: Gao, Qingzhu, et al.
Publicado: (2023)

Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting
por: Xiong, J, et al.
Publicado: (2015)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities
por: Kao, Tzu-Jen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e6h9tm7g9ibce87dmskk3cojib